Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach - The case study of Canada

Journal of Urban Health

Volumn 81, Issue 3, 2004, Pages 428-447

  Fischer, Benedikt ^a,b   Haydon, Emma ^b   Rehm, Jürgen ^a,b   Krajden, Mel ^c   Reimer, Jens ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Centre for Interdisciplinary Addiction Research   (Germany)

Author keywords

Canada; Hepatitis C; Injection drug use; Prevention; Treatment

Indexed keywords

ALCOHOL; ILLICIT DRUG; INTERFERON; METHADONE; PEGINTERFERON; RIBAVIRIN;

ANXIETY; ARTICLE; CANADA; CASE STUDY; DEPRESSION; DRUG ALCOHOL INTERACTION; DRUG WITHDRAWAL; FEASIBILITY STUDY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ABUSE; MENTAL DISEASE; MOTIVATION; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; REINFECTION; SIDE EFFECT; SOCIAL ENVIRONMENT; VIRUS TRANSMISSION;

CANADA; COMORBIDITY; HEPATITIS C; HUMANS; PROSTITUTION; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 4344576522     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1093/jurban/jth128     Document Type: Article

References (165)

1. Remis RS, Hogg RS, Krahn MD, Preiksaitis JK, Sherman M. Estimating the Number of Blood Transfusion Recipients Infected by Hepatitis C in Canada, 1960-1985 and 1990-1992. Ottawa, Ontario, Canada: Laboratory Centre for Disease Control; 1998.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New Engl J Med. 1999;341:556-562.
3. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis. 1997;1:559-568.
4. Zou S, Tepper M, Giulivi A. Current status of hepatitis C in Canada. Can J Public Health. 2000;91:S10-S15.
5. Patrick D, Buxton J, Bigham M, Mathias R. Public health and hepatitis C. Can J Public Health. 2000;91:S18-S21.
6. World Health Organization. The world health report 1998 - life in the 21st century: a vision for all. Wkly Epidemiol Record. 1998;73:145-152.
7. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med. 1992;327:1899-1905.
8. Seeff LB. Natural history of hepatitis C. Hepatology. 1997;26:21S-28S.
9. Zou S, Forrester L, Giulivi A. Hepatitis C update. Can J Public Health. 2003;94:127-129.
10. Zou S, Teppe M, ElSaadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol. 2000;14:575-580.
11. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality and costs in the United States. Am J Public Health. 2000;90:1562-1569.
12. Cherubin CE, Sapira JD. The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later. Ann Intern Med. 1993;119:1017-1028.
13. Flamm SL, Parker RA, Chopra S. Risk factors associated with chronic hepatitis C virus infection: limited frequency of an unidentified source of transmission. Am J Gastroenterol. 1998;93:597-600.
14. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334:1691-1696.
15. Tortu S, Neaigus A, McMahon J, Hagen D. Hepatitis C among noninjecting drug users: a report. Subst Use Misuse. 2001;36:523-534.
16. Harsch HH, Pankiewicz J, Bloom AS, et al. Hepatitis C virus infection in cocaine users - a silent epidemic. Community Mental Health J. 2000;36:225-233.
17. Strader DB. Understudied populations with hepatitis C. Hepatology. 2002;36:S226-S236.
18. Hagan H. Hepatitis C virus transmission dynamics in injection drug users. Subst Use Misuse. 1998;35:1197-1212.
19. Kelen GD, Green GB, Purcell RH, et al. Hepatitis B and hepatitis C in emergency department patients. N Engl J Med. 1992;326:1399-1404.
20. Crofts N, Hopper JL, Bowden DS, Breschkin AM, Milner R, Locarnini SA. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust. 1993; 59:237-241.
21. Coppola RC, Masia G, di Martino ML, et al. Sexual behaviour and multiple infections in drug abusers. Eur J Epidemiol. 1996;12:429-435.
22. Diamantis I, Bassetti S, Erb P, Ladewig D, Gyr K, Battegay M. High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol. 1997;26:794-797.
23. Garfein R, Doherty MC, Monterroso ER, Thomas DL, Nelson K, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immun Defic Syndr. 1998;18:S11-S19.
24. Palitzsch KD, Hottentrager B, Schlottman K, et al. Prevalence of antibodies against hepatitis C virus in the adult German population. Eur J Gastroenterol Hepatol. 1999;11:1215-1220.
25. Fugslang T, Fouchard JR, Ege PP. Prevalence of HIV and hepatitis B and C among drug addicts in the city of Copenhagen. Ugeskr Laeger. 2000;162:3860-3864.
26. Denis B, Dedobbeleer M, Collet T, et al. High prevalence of hepatitis virus infection in Belgian intravenous drug users and potential role of the "cotton-filter" in transmission: the GEMT study. Acta Gastroenterol Belg. 2000;63:147-153.
27. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin J, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91:42-46.
28. Diaz T, Des Jarlais D, Vlahov D, et al. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health. 2001;91:23-30.
29. Fischer B, Rehm J, Baliunas D, et al. OPICAN Toronto site: Baseline data overview. Paper presented at: IHRT All-Projects Conference; Sept. 28-29, 2002; Toronto, Ontario, Canada.
30. Patrick D, Tyndall M, Cornelisse P, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ. 2001;165:889-895.
31. Lamothe F, Vincelette J, Bruneau J, et al. Prevalence, seroconversion rates and risk factors for hepatitis B core, hepatitis C and HIV antibodies among intravenous drug users (IDU) of the Saint-Luc Cohort (abstract 221). 6th Annual Canadian Conference on HIV/AIDS Research, May 1997. Can J Infect Dis. 1997;:28A.
32. Fischer B, Medved W, Gliksman L, Rehm J. Illicit opiates in Toronto: a profile of current users. Addict Res Theory. 1999;7:377-415.
33. Miller CL, Spittal PM, Laliberte N, Li K, O'Shaughnessy M, Schechter M. Risk factors for HIV and HCV prevalence and incidence among young injection drug users in a Canadian city coping with an epidemic. Paper presented at: 11th Annual Canadian Conference on HIV/AIDS Research; April 25-28, 2002; Winnipeg, Manitoba, Canada.
34. Poulin C, Single E, Fralick P. Canadian Community Epidemiology Network on Drug Use (CCENDU): Second National Report. Ottawa, Ontario, Canada: Canadian Centre on Substance Abuse; 1999.
35. Serfaty MA, Lawrie A, Smith B, et al. Risk factors and medical follow-up of drug users tested for hepatitis C-can the risk of transmission be reduced? Drug Alcohol Rev. 1997;16:339-347.
36. Meili D, Marcinko J, Bertisch-Moellenhoff B, et al. Possible transmission routes of viral diseases during communal preparation of drugs for i.v. use. Suchttherapie. 2002;3:S20-S26.
37. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002;186:1558-1564.
38. Bourgois P, Bruneau J. Needle exchange, HIV infection, and the politics of science: confronting Canada's cocaine injection epidemic with participant observation. Med Anthropol. 2000;18:325-350.
39. Short L, Bell D. Risk of occupational infection with blood-borne pathogens in operating and delivery-room settings. Am J Infect Control. 1993;21:343-350.
40. Moss AR, Hahn JA. Invited commentary: needle exchange-no help for hepatitis? Am J Epidemiol. 1999;149:214-216.
41. Wood E, Tyndall MW, Spittal PM, et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ. 2001; 165:405-410.
42. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine. 1995;74:212-220.
43. Porter J, Bonilla L, Drucker E. Methods of smoking crack as a potential risk factor for HIV infection: crack smokers' perceptions and behavior. Contemp Drug Probl. 1997;24:219-347.
44. Archibald CP, Ofner M, Strathdee SA, et al. Factors associated with frequent needle exchange program attendance in injection drug users in Vancouver, Canada. J Acquir Immune Defic Syndr. 1998;17:160-166.
45. Kwiatkowski CF, Corsi KF, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction. 2002;97:1289-1294.
46. Davis GL, Esteban-Mur R, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998;339:1493-1499.
47. + lymphocytes in acute and chronic hepatitis. J Mol Med. 1996;74:583-588.
48. Tubaro E, Santiangeli C, Belogi L, et al. Methadone versus morphine: comparison of their effect on phagocytic functions. Int J Immunopharmacol. 1987;9:79-88.
49. Cushman P, Gupta S, Grieco MH. Immunological studies in methadone maintained patients. Int J Addict. 1977;12:241-253.
50. Pellegrino T, Bayer BM. In vivo effects of cocaine on immune cell function. J Neuroimmunol. 1998;83:139-147.
51. Roy E, Haley N, Leclerc P, Boivin J-F, Cedras L, Vincelette J. Risk factors for hepatitis C virus infection among street youths. CMAJ. 2001;165:557-560.
52. Mehta S, Cox A, Hoover D, et al. Protection against persistence of hepatitis C. Lancet. 2002;359:1478-1483.
53. Dore G, Freeman A, Kaldor J. Immunity against hepatitis C virus infection. Lancet. 2002;360:1019-1020.
54. Post J, Freeman A, Harvey C, French R, Lloyd A. Immunity against hepatitis C virus infection. Lancet. 2002;360:1020.
55. El-Serag H, Bhupinderjut A, Richardson P, Rabeneck L. Association between hepatitis C infection and other infectious diseases: a case for targeted screening? Am J Gastroenterol. 2003;98:167-174.
56. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology. 2002;36:S201-S209.
57. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30:S77-S84.
58. Vento S, Cainelli F. Does hepatitis C virus cause severe liver disease only in people who drink alcohol? Lancet Infect Dis. 2002;2:303-309.
59. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry. 2000;157:867-876.
60. Booth RE, Kwiatkowski CF, Chitwood DD. Sex related HIV risk behaviors: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. Drug Alcohol Depend. 2000;58:219-226.
61. Ottaway CA, Erickson PG. Frequent medical visits by cocaine-using subjects in a Canadian community: an invisible problem for health practitioners? J Subst Abuse Treat. 1997;14:423-429.
62. Palepu A, Strathdee SA, Hogg RS, et al. The social determinants of emergency department and hospital use by injection drug users in Canada. J Urban Health. 1999;76:409-418.
63. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology. 2002;36:S99-S105.
64. Romanowski B, Preiksaitis J, Campbell P, Fenton J. Hepatitis C seroprevalence and risk behaviors in patients attending sexually transmitted disease clinics. Sex Transm Dis. 2003;30:33-38.
65. Fuller CM, Vlahov D, Ompad DC, Shah N, Arria A, Strathdee SA. High-risk behaviors associated with transition from illicit non-injection to injection drug use among adolescent and young adult drug users: a case-control study. Drug Alcohol Depend. 2002;66:189-198.
66. Myers T, Millson M, Rigby J, et al. A comparison of the determinants of safe injecting and condom use among injecting drug users. Addiction. 1995;90:217-226.
67. Inciardi JA. The Miami sex-for-crack market. In: Ratner MS, ed. Crack Pipe as Pimp: an Ethnographic Investigation of Sex-for-Crack Exchanges. New York: Lexington Books; 1993:36-68.
68. Hwang L-Y, Ross MW, Zack C, Bull L, Rickman K, Holleman M. Prevalence of sexually transmitted infections and associated risk factors among populations of drug abusers. Clin Infect Dis. 2000;31:920-926.
69. Haydon E, Fischer B, Strike C, Rehm J, Millson P. Crack Use and Hepatitis C in Canada: a Review of Research Evidence and Questions. Ottawa, Ontario, Canada: Health Canada; 2002.
70. Evans R, Barer M, Marmor T. Why Are Some People Healthy and Others Not? New York: A. de Gruyter; 1994.
71. Canadian HIV/AIDS Legal Network. Injection Drug Use and HIV: Legal and Ethical Issues. Montreal, Quebec, Canada: Canadian HIV/AIDS Legal Network; 1999.
72. Page-Shafer KA, Cahoon-Young B, Klausner JD, et al. Hepatitis C virus infection in young, low-income women: the role of sexually transmitted infection as a potential cofactor for HCV infection. Am J Public Health. 2002;92:670-676.
73. Logan TK, Leukefeld C. Sexual and drug use behaviors among female crack uers: a multi-site sample. Drug Alcohol Depend. 2000;58:237-245.
74. Schroeder JR, Latkin CA, Hoover DR, Curry AD, Knowlton AR, Celetano DD. Illicit drug use in one's social network and in one's neighborhood predicts individual heroin and cocaine use. Ann Epidemiol. 2001;11:389-394.
75. Lovell AM. Risking risk: the influence of types of capital and social networks on the injection practices of drug users. Soc Sci Med. 2002;55:803-821.
76. Mandell W, Vlahov D, Latkin C, Oziemkowska M, Cohn S. Correlates of needle sharing among injection drug users. Am J Public Health. 1994;84:920-924.
77. Sherman S, Latkin C, Gielen A. Social factors related to syringe sharing among injecting partners: a focus on gender. Subst Use Misuse. 2001;36:2113-2136.
78. Patrick D, Strathdee SA, Archibald CP, et al. Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver. Int J STD AIDS. 1997;8:437-445.
79. Harvey E, Strathdee S, Patrick D, et al. A qualitative investigation into an HIV outbreak among injection drug users in Vancouver, British Columbia. AIDS Care. 1998;10:313-321.
80. Latkin CA, Mandell W, Vlahov D, Oziemkowska M, Celetano DD. People and places: behavioral settings and personal network characteristics as correlates of needle sharing. J Acquir Immun Defic Syndr. 1996;13:273-280.
81. Strathdee S, Patrick D, Archibald CP, et al. Social determinants predict needle-sharing behaviour among injection drug users in Vancouver, Canada. Addiction. 1997;92:1339-1347.
82. Estrada AL. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C and tuberculosis among minority injection drug users. Public Health Rep. 2002;117:S126-S134.
83. Craib KJP, Spittal PM, Wood E, et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ. 2003;68:19-24.
84. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
85. Fried M, Shiffman M, Reddy K, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
86. Nolte FS. Hepatitis C virus genotyping: clinical implications and methods. Mol Diagn. 2001;6:265-277.
87. Chaudhary RK, Tepper M, Eisaadany S, Gully PR. Distribution of hepatitis C genotypes in Canada: results from the LCDC sentinel health unit surveillance system. Can J Infect Dis. 1999;10:53-56.
88. Kleter B, Brouwer JT, Nevens F, et al. Hepatitis C virus genotypes: epidemiological and clinical associations. Liver. 1998;18:32-38.
89. Bourlière M, Barberin JM, Rotily M, et al. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat. 2002;9:62-70.
90. Andonov A, Chaudhary RK. Genotyping of Canadian hepatitis C virus isolates by PCR. J Clin Microbiol. 1994;32:2031-2034.
91. Abraham HD, Degli-Esposti S, Marino L. Seroprevalence of hepatitis C in a sample of middle class substance abusers. J Addict Dis. 1999;18:77-87.
92. Ramalho R, Costa A, Pires A, et al. Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C. Dig Dis Sci. 2000; 45:182-187.
93. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.
94. Fried MW, Shiffman ML, Reddy RK, et al. Pegylated (40 kDa) interferon alfa-2a (Pegasys) in combination with ribavirin: efficacy and safety results from a phase III, randomised, actively controlled, multi-center study. Gastroenterology. 2001;5:55.
95. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
96. Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis C viruses. AIDS. In press.
97. Bhattacharya R, Shuhart M. Hepatitis C and alcohol: interactions, outcomes and implications. J Clin Gastroenterol. 2003;36:242-252.
98. Mueser K, Yarnold P, Bellack A. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatr Scand. 1992;85:48-55.
99. Brown R, Monti P, Myers M, et al. Depression among cocaine abusers in treatment: relation to cocaine and alcohol use and treatment outcome. Am J Psychiatry. 1998;155:220-225.
100. Flynn P, Craddock S, Luckey J, Hubbard R, Dunteman G. Comorbidity of antisocial personality and mood disorders among psychoactive substance-dependent treatment clients. J Personal Disord. 1996;10:56-67.
101. Weiss R, Martinez-Raga J, Hufford C. The significance of a coexisting opioid use disorder in cocaine dependence: an empirical study. Am J Drug Alcohol Abuse. 1996; 22:173-184.
102. Magura S, Kang S-Y, Nwakeze P, Demsky S. Temporal patterns of heroin and cocaine use among methadone patients. Subst Use Misuse. 1998;33:2441-2467.
103. Krausz M, Degkwitz P, Kuhne A, Verthein U. Comorbidity of opiate dependence and mental disorders. Addict Behav. 1998;23:767-783.
104. Marlowe D, Husband S, Lamb R, Kirby K, Iguchi M, Platt J. Psychiatric comorbidity in cocaine dependence. Diverging trends, axis II spectrum, and gender differentials. Am J Addict. 1995;4:70-81.
105. Khantzian E. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry. 1985;142:1264.
106. Murphy S, Khantzian E. Addiction as a "self-medication" disorder: application of ego psychology to the treatment of substance abuse. In: Washton A, ed. Psychotherapy and Substance Abuse: a Practitioner's Handbook. London: Guilford Press; 1995:161-175.
107. Khantzian E. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry. 1997;4:231-224.
108. Gutfreund KS, Bain VG. Chronic viral hepatitis C: management update. CMAJ. 2000;162:827-833.
109. Crofts N, Louie R, Loff B. The next plague: stigmatization and discrimination related to hepatitis C virus infection in Australia. Health Hum Rights. 1997;2:2.
110. Treloar CJ, Hopwood MN, Loveday SK. Hepatitis C-related discrimination in healthcare. Med J Aust. 2002;177:233-234.
111. Hagan H, Snyder N, Hough E, et alet al. Case-reporting of acute hepatitis B and C among injection drug users. J Urban Health. 2002;79:579-585.
112. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345:211-214.
113. National Institutes of Health. Management of hepatitis C. NIH Consens Statement Online. 1997;15:1-41.
114. Heathcote JE, Yim C, Thai Q, Sherker A. Your Personal Health Series (Canadian Medical Association): Hepatitis C. Toronto, Ontario, Canada: Key Porter Books; 2001.
115. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis. 2003;36:97-100.
116. Huber M, Schmid P, Vernazza P, Meili D. Reasons for the lack of treatment of hepatitis C infection in drug dependent patients in opiate substitution. Suchttherapie. 2002;3:S27-S30.
117. Berkman LF, Kawachi I. A historical framework for social epidemiology. In: Berkman LF, Kawachi I, eds. Social Epidemiology. Oxford, UK: Oxford University Press; 2000:3-12.
118. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. Engl J Med. 2001;345:215-217.
119. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology. 2002; 36:S121-S127.
120. Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systematic review. Hepatology. 2002;36:S135-S144.
121. Schaefer M. Neuro-psychiatric side effects of interferon-alpha in drug addicts: reasons, frequency and therapy. Suchttherapie. 2002;3:S72-S77.
122. National Institutes of Health. Management of Hepatitis C: Final Statement. Washington, DC: National Institutes of Health; 2002.
123. Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon-2b plus ribavirin versus interferon-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52:425-432.
124. Salomon J, Weinstein M, Hammitt J, Goldie S. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290:228-237.
125. Sagmeister M, Wong JB, Mullhaupt B, Renner EL. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol. 2001;13:483-488.
126. Backmund M. Interferon therapy and detoxification treatment. Suchttherapie. 2002;3:S67-S71.
127. Backmund M, Meyer K, von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34:188-193.
128. Neri S, Bruno CM, Abate G, et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther. 2002;24:1627-1635.
129. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443-451.
130. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend. 2002;67:117-123.
131. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injection drug users: 5 years' follow-up. Eur Addict Res. 2002;8:45-49.
132. Bickel W, Vuchinich R. Reframing Health Behavior Change With Behavioral Economics. Mahwah, NJ: Erlbaum; 2000.
133. World Health Organization. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization; 2002.
134. Stein M, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend. 2001;61:211-215.
135. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002;36:S210-S219.
136. Strathdee S, van Ameijden EJ, Mesquita F, Wodak A, Rana S, Vlahov D. Can HIV epidemics among injection drug users be prevented? AIDS. 1998;12:S71-S79.
137. Broadhead RS, Heckathorn DD, Weakliem DL, et al. Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven intervention. Public Health Rep. 1998;113:42-57.
138. Fischer B, Rehm J, Blitz-Miller T. Injection drug use and preventive measures: a comparison of Canadian and Western European jurisdictions over time. CMAJ. 2000;162:1709-1713.
139. Brands J, Brands B, Marsh D. The expansion of methadone prescribing in Ontario, 1996-1997. Addict Res Theory. 2000;8:485-496.
140. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-1069.
141. Marco A, Cayla JA, Serra M, et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Eur Respirol J. 1998;12:967-971.
142. Gourevitch MN, Wasserman W, Panero MS, Selwyn PA. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis. 1996;15:93-104.
143. Renault P, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987;147:1577-1580.
144. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:S237-S244.
145. Frei A, Rehm J. Die Prävalenz psychischer Komorbidität unter Opiatabhängigen: eine Metaanalyse bisheriger Studien. Psychiatr Prax. 2002;29:258-262.
146. Van Thiel DH, Friedlander L, De Maria N, Molloy PJ, Kania RJ, Colantoni A. Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepatogastroenterology. 1998;45:328-330.
147. Musselman DL, Lawson DH, Gunnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-966.
148. Kraus MR, Schafer A, Scheurlen M, Miller AH, Musselman DL, Nemeroff CB. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;345:375-376.
149. Leshner A. Addiction is a brain disease, and it matters. Science. 1997;278:45-47.
150. Hagan H, DesJarlais DC, Freidman SR, Purchase D, Alter M.J. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health. 1995;85:1531-1537.
151. Trautmann F. Peer support as a method of risk reduction in injection drug-user communities: experiences in Dutch projects and the "European peer support project." J Drug Issues. 1995;25:617-628.
152. Hankins C. Syringe exchange in Canada: good but not enough to stem the HIV tide. Subst Use Misuse. 1998;33:1129-1145.
153. Fischer B, Rehm J, Kim G, Robins A. Safer injection facilities (SIFs) for injection drug users (IDUs) in Canada: a review and call for an evidence-focused pilot trial. Can J Public Health. 2002;93:336-338.
154. Dolan K, Kimber J, Fry C, Fitzgerald J, McDonald D, Trautmann F. Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia. Drug Alcohol Rev. 2000;19:337-346.
155. Heimer R, Clair S, Grau LE, et al. Hepatitis-related knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction. 2002;97:1277-1287.
156. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy. Drug Alcohol Depend. 2000;59:17-31.
157. Marsch L. The efficacy of methadone maintenance interventions in reducing opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93:515-532.
158. Woodward A, Kawachi, I. Why reduce health inequalities? J Epidemiol Community Health. 2000;54:923-929.
159. Link BG, Phelan J. Social conditions as fundamental causes of disease. J Health Soc Behav. 1995;35:80-94.
160. EMCDDA European Monitoring Centre for Drugs and Drug Addiction. Study on Assistance to Drug Users in Prisons. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction; 2001.
161. Glannon W. Responsibility, alcoholism, and liver transplantation. J Med Philos. 1998;23:31-49.
162. Caplan AL. Ethics of casting the first stone: personal responsibility, rationing and transplants. Alcohol Clin Exp Res. 1994;18:219-221.
163. Rehm J, Fischer B, Haydon E, Room R. Abstinence ideology and somatic treatment for addicts-ethical considerations. Addict Res Theory. 2003;11:287-293.
164. Remis R. Estimating the incidence and prevalence of hepatitis C in Canada. Presented at the Second Canadian Conference on Hepatitis C: New Knowledge, New Hope, Vancouver, BC, March 27-30, 2004.
165. Sherman M, Bain V, Villeneuve J-P, et al. Management of Viral Hepatitis: A Canadian Consensus Conference. Toronto; 2004.